Literature DB >> 3082581

Cefotaxime metabolism by hemolyzed blood: quantitation and inhibition of the deacetylation reaction.

W D Welch, R E Bawdon.   

Abstract

The metabolism of cefotaxime (CTX) by hemolyzed blood at different concentrations, time intervals, and temperatures was studied. Cefotaxime and desacetylcefotaxime (DES) levels were quantitated by reverse phase high pressure liquid chromatography. When CTX was added to tubes with 10% hemolysis, CTX/DES levels (micrograms per milliliter) were 123/134, 161/114, and 202/60 at 37 degrees C, room temperature, and 4 degrees C, respectively, after a 1 hr incubation. No reduction in CTX was observed in control experiments (10% blood, no hemolysis) at these temperatures after 1 hr; 200 +/- 23 micrograms/ml CTX; 5 +/- 2 micrograms/ml DES. The disappearance half-life of CTX in 10% hemolyzed blood at 37 degrees C was 45.7 min and at room temperature 84.3 min (p less than 0.001). The addition of the enzyme inhibitors ethylenediaminetetraacetic acid and p-hydroxymercuibenzoate reduced the metabolism of CTX in the presence of 10% hemolysis after 1 hr at 37 degrees C from 41% to 19% with ethylenediaminetetraacetic acid (0.45 mM) and to 0% with p-hydroxymercuibenzoate (10 mM). Our results suggest that for accurate determinations of CTX serum levels, which often have some degree of hemolysis, such specimens should be collected in tubes with ethylenediaminetetraacetic acid or p-hydroxymercuibenzoate and transported at 4 degrees C.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082581     DOI: 10.1016/0732-8893(86)90145-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Penetration of cefotaxime into respiratory secretions.

Authors:  R B Fick; M R Alexander; R A Prince; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

3.  Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children.

Authors:  Yarmarly C Guerra Valero; Tavey Dorofaeff; Jason A Roberts; Jeffrey Lipman; Mark G Coulthard; Louise Sparkes; Steven C Wallis; Suzanne L Parker
Journal:  Anal Bioanal Chem       Date:  2021-05-26       Impact factor: 4.142

4.  Heat stabilization of blood spot samples for determination of metabolically unstable drug compounds.

Authors:  Daniel Blessborn; Karl Sköld; David Zeeberg; Karnrawee Kaewkhao; Olof Sköld; Martin Ahnoff
Journal:  Bioanalysis       Date:  2013-01       Impact factor: 2.681

5.  Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime.

Authors:  F Vallée; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans.

Authors:  J Sjölin; N Eriksson; P Arneborn; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

7.  Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?

Authors:  Yarmarly C Guerra Valero; Tavey Dorofaeff; Mark G Coulthard; Louise Sparkes; Jeffrey Lipman; Steven C Wallis; Jason A Roberts; Suzanne L Parker
Journal:  J Antimicrob Chemother       Date:  2022-07-28       Impact factor: 5.758

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.